Why New Generic Products Could Boost TEVA’s Revenue Growth
Recent product launches
In August 2017, Teva Pharmaceutical Industries (TEVA) launched the generic version of Eli Lilly’s (LLY) Axiron. Axiron is a topical solution of testosterone prescribed for the treatment of adult males with low or no testosterone because of a medical condition.
In July 2017, Teva launched the generic version of Galderma’s Epiduo gel. Epiduo gel is a combination of adapalene and benzoyl peroxide used for the topical treatment of acne vulgaris in individuals aged nine years or older. According to IMS Health March 2017 statistics, in US markets, adapalene and benzoyl peroxide gel had annual sales of ~$251 million.
Interested in TEVA? Don't miss the next report.
Receive e-mail alerts for new research on TEVA
In June 2017, Teva also launched the generic version of Novartis’ (NVS) Pataday in US markets. Pataday (olopatadine hydrochloride) ophthalmic solution is used for the treatment of ocular itching due to allergic conjunctivitis. According to IMS Health statistics of March 2017, in the US, Pataday had generated revenues of ~$303 million.
Launch of generic Ezetimibe-regimens
In June 2017, Teva launched the generic versions of Merck’s (MRK) Zetia. Zetia (ezetimibe) is prescribed for the management of total cholesterol and low-density lipoprotein cholesterol in the blood. Ezetimibe is used in individuals who are unable to control their cholesterol levels in the blood by diet and exercises alone.
In April 2017, Teva launched the generic version of Merck’s Vytorin. Vytorin is a combination of ezetimibe and simvastatin tablets in the US. According to IMS Health statistics of March 2017, ezetimibe tablets and Vytorin had annual revenues of ~$2.7 billion and $678 million, respectively.
Notably, the BLDRS Developed Markets 100 ADR Index Fund (ADRD) has ~0.46% of its total portfolio holdings in TEVA.